TY - JOUR
T1 - Efficacy of sucrose and povidone–iodine mixtures in peritoneal dialysis catheter exit-site care
AU - Nakayama, Takashin
AU - Morimoto, Kohkichi
AU - Uchiyama, Kiyotaka
AU - Washida, Naoki
AU - Kusahana, Ei
AU - Hama, Eriko Yoshida
AU - Mitsuno, Ryunosuke
AU - Tonomura, Shun
AU - Yoshimoto, Norifumi
AU - Hishikawa, Akihito
AU - Hagiwara, Aika
AU - Azegami, Tatsuhiko
AU - Yoshino, Jun
AU - Monkawa, Toshiaki
AU - Yoshida, Tadashi
AU - Yamaguchi, Shintaro
AU - Hayashi, Kaori
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Background: Exit-site infection (ESI) is a common recurring complication in patients undergoing peritoneal dialysis (PD). Sucrose and povidone–iodine (SPI) mixtures, antimicrobial ointments that promote wound healing, have been used for the treatment of ulcers and burns, but their efficacy in exit–site care is still unclear. Methods: This single-center retrospective observational study included patients who underwent PD between May 2010 and June 2022 and presented with episodes of ESI. Patients were divided into SPI and non-SPI groups and followed up from initial ESI onset until PD cessation, death, transfer to another facility, or June 2023. Results: Among the 82 patients (mean age 62, [54–72] years), 23 were treated with SPI. The median follow-up duration was 39 months (range, 14–64), with an overall ESI incidence of 0.70 episodes per patient-year. Additionally, 43.1% of second and 25.6% of third ESI were caused by the same pathogen as the first. The log-rank test demonstrated significantly better second and third ESI-free survival in the SPI group than that in the non-SPI group (p < 0.01 and p < 0.01, respectively). In a Cox regression analysis, adjusting for potential confounders, SPI use was a significant predictor of decreased second and third ESI episodes (hazard ratio [HR], 0.22; 95% confidence interval [CI], 0.10–0.52 and HR, 0.22; 95%CI, 0.07–0.73, respectively). Conclusions: Our results showed that the use of SPI may be a promising option for preventing the incidence of ESI in patients with PD. Trial registration: This study was approved by the Keio University School of Medicine Ethics Committee (approval number 20231078) on August 28, 2023. Retrospectively registered.
AB - Background: Exit-site infection (ESI) is a common recurring complication in patients undergoing peritoneal dialysis (PD). Sucrose and povidone–iodine (SPI) mixtures, antimicrobial ointments that promote wound healing, have been used for the treatment of ulcers and burns, but their efficacy in exit–site care is still unclear. Methods: This single-center retrospective observational study included patients who underwent PD between May 2010 and June 2022 and presented with episodes of ESI. Patients were divided into SPI and non-SPI groups and followed up from initial ESI onset until PD cessation, death, transfer to another facility, or June 2023. Results: Among the 82 patients (mean age 62, [54–72] years), 23 were treated with SPI. The median follow-up duration was 39 months (range, 14–64), with an overall ESI incidence of 0.70 episodes per patient-year. Additionally, 43.1% of second and 25.6% of third ESI were caused by the same pathogen as the first. The log-rank test demonstrated significantly better second and third ESI-free survival in the SPI group than that in the non-SPI group (p < 0.01 and p < 0.01, respectively). In a Cox regression analysis, adjusting for potential confounders, SPI use was a significant predictor of decreased second and third ESI episodes (hazard ratio [HR], 0.22; 95% confidence interval [CI], 0.10–0.52 and HR, 0.22; 95%CI, 0.07–0.73, respectively). Conclusions: Our results showed that the use of SPI may be a promising option for preventing the incidence of ESI in patients with PD. Trial registration: This study was approved by the Keio University School of Medicine Ethics Committee (approval number 20231078) on August 28, 2023. Retrospectively registered.
KW - Exit-site infections
KW - Peritoneal dialysis
KW - Povidone–iodine
KW - Sucrose
KW - Tunnel infections
UR - http://www.scopus.com/inward/record.url?scp=85191889108&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85191889108&partnerID=8YFLogxK
U2 - 10.1186/s12882-024-03591-1
DO - 10.1186/s12882-024-03591-1
M3 - Article
C2 - 38698327
AN - SCOPUS:85191889108
SN - 1471-2369
VL - 25
JO - BMC Nephrology
JF - BMC Nephrology
IS - 1
M1 - 151
ER -